BAYRY Stock Recent News

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease hot flashes in a third late-stage trial, providing some relief for its pharmaceuticals unit that is reeling from a recent development setback.

Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now.

Bayer CEO Bill Anderson joins 'Squawk on the Street' to discuss why the company hasn't broken up parts of the business, why the current strategy is the best way to go, and more.

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.

Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfront.

The Stoxx 600 index will be in the spotlight this week as the European Central Bank (ECB) delivers its second interest rate decision of the year. The index, which tracks the biggest European companies, surged to a record high of €497, which was about 30% above its lowest point in December 2022.

Bayer is not planning to announce a split of its company at its Capital Markets Day next week, Handelsblatt said on Friday, citing people familiar with the matter.

Bayer said that the head of its consumer health division, Heiko Schipper, would be replaced by Julio Triana, currently the unit's head of commercial operations region international.